人乳头瘤病毒相关妇科肿瘤：筛查与预防
Human papillomavirus-related gynecologic neoplasms: screening and prevention.
作者信息
Growdon Whitfield B, Del Carmen Marcela
机构信息
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Massachusetts General Hospital, Harvard Medical School Boston, MA.
出版信息
Rev Obstet Gynecol. 2008 Fall;1(4):154-61.
Abstract
The recent recognition of oncogenic human papillomavirus (HPV) as a key component of female lower genital tract malignancies has led to significant changes in many screening and prevention guidelines for cervical cancer, and, combined with the advent of vaccination, will likely have sweeping repercussions on the incidence of cervical, vulvar, and vaginal carcinoma. This article focuses on the specific principles of cancer screening and prevention with an emphasis on HPV-mediated disease.
摘要
近期，致癌性人乳头瘤病毒（HPV）被确认为女性下生殖道恶性肿瘤的关键组成部分，这使得许多宫颈癌筛查和预防指南发生了重大变化，并且，随着疫苗的问世，可能会对宫颈癌、外阴癌和阴道癌的发病率产生广泛影响。本文重点关注癌症筛查和预防的具体原则，尤其着重于HPV介导的疾病。
相似文献
1
Human papillomavirus-related gynecologic neoplasms: screening and prevention.
Rev Obstet Gynecol. 2008 Fall;1(4):154-61.
2
From the monovalent to the nine-valent HPV vaccine.
Clin Microbiol Infect. 2015 Sep;21(9):827-33. doi: 10.1016/j.cmi.2015.05.001. Epub 2015 May 14.
3
Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer.
Obstet Gynecol. 2006 Dec;108(6):1361-8. doi: 10.1097/01.AOG.0000245786.86267.80.
4
Improving Knowledge and Awareness of Human Papillomavirus-Associated Gynecologic Cancers: Results from the National Comprehensive Cancer Control Program/Inside Knowledge Collaboration.
J Womens Health (Larchmt). 2018 Aug;27(8):955-964. doi: 10.1089/jwh.2018.7289.
5
Prevention of Human Papillomavirus Infection. Beyond Cervical Cancer: A Brief Review.
Acta Med Port. 2020 Mar 2;33(3):198-201. doi: 10.20344/amp.12259.
6
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.
7
Update of HPV-associated female genital cancers in the United States, 1999-2004.
J Womens Health (Larchmt). 2009 Nov;18(11):1731-8. doi: 10.1089/jwh.2009.1570.
8
Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors.
Obstet Gynecol. 2009 Apr;113(4):917-924. doi: 10.1097/AOG.0b013e31819bd6e0.
9
Human Papillomavirus Selected Properties and Related Cervical Cancer Prevention Issues.
Curr Pharm Des. 2020;26(18):2073-2086. doi: 10.2174/1381612826666200422094205.
10
Epidemiological dynamic modeling of human papillomavirus-related diseases to assess vaccination strategies in Argentina.
Medicina (B Aires). 2018;78(5):315-328.
引用本文的文献
1
MetaShot: an accurate workflow for taxon classification of host-associated microbiome from shotgun metagenomic data.
Bioinformatics. 2017 Jun 1;33(11):1730-1732. doi: 10.1093/bioinformatics/btx036.
本文引用的文献
1
Decreased survival in EGFR gene amplified vulvar carcinoma.
Gynecol Oncol. 2008 Nov;111(2):289-97. doi: 10.1016/j.ygyno.2008.07.038. Epub 2008 Sep 3.
2
Natural history and epidemiology of HPV infection and cervical cancer.
Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S4-7. doi: 10.1016/j.ygyno.2008.07.045.
3
Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan.
Gynecol Oncol. 2008 Nov;111(2):188-96. doi: 10.1016/j.ygyno.2008.07.032. Epub 2008 Aug 30.
4
Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature.
Gynecol Oncol. 2008 Sep;110(3 Suppl 1):S1-10. doi: 10.1016/j.ygyno.2008.05.036. Epub 2008 Jul 24.
5
A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
Gynecol Oncol. 2008 Sep;110(3 Suppl 1):S18-25. doi: 10.1016/j.ygyno.2008.06.027. Epub 2008 Jul 23.
6
Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age.
Gynecol Oncol. 2008 Sep;110(3 Suppl 1):S11-7. doi: 10.1016/j.ygyno.2008.06.029. Epub 2008 Jul 22.
7
Clinical role of cervical cancer vaccination: when and whom to vaccinate?
Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S15-6. doi: 10.1016/j.ygyno.2008.06.015. Epub 2008 Jul 17.
8
A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States.
Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1611-22. doi: 10.1158/1055-9965.EPI-07-2922.
9
Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India.
Br J Cancer. 2008 Jul 22;99(2):230-8. doi: 10.1038/sj.bjc.6604462. Epub 2008 Jul 8.
10
Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation.
Value Health. 2008 Dec;11(7):1022-32. doi: 10.1111/j.1524-4733.2008.00342.x. Epub 2008 May 16.
Zotero 插件